At the news
? BEARISHIMPACT 6/10 8-K filed Nov 9, 2026 at 16:02 ET
Aldeyra Therapeutics requested FDA transfer of its ADX-2191 IND for primary vitreoretinal lymphoma from the Division of Ophthalmology to the Division of Hematologic Malignancies 2, and withdrew its Special Protocol Assessment agreement. The regulatory path is now uncertain, the planned clinical trial is on hold, and the program faces potential delays, redesign, or discontinuation.
- Aldeyra requested FDA transfer of ADX-2191 IND from Division of Ophthalmology to Division of Hematologic Malignancies 2
- Aldeyra withdrew the Special Protocol Assessment (SPA) protocol for ADX-2191 in PVRL
- Company does not expect to initiate the SPA-contemplated clinical trial while jurisdictional request is pending
- ADX-2191 previously received a Complete Response Letter in June 2023 for lack of substantial evidence of effectiveness
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access